Lilly Calls It Quits on Baricitinib's Development for Lupus

The company said it is stopping phase 3 trials because of disappointing results.

Related Keywords

Japan , Eli Lilly , European Union , Drug Administration , Development For Atopic Dermatitis , Complete Response Letter , Systemic Lupus Erythematosus , Sale , Clinical Research , Clinical Trials , Linical Studies , Lupus , Atopic Dermatitis , Dermatitis , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Anti Tnf , Anti Tumor Necrosis Factor , Biologic Therapy , Europe , European , Rheumatoid Arthritis , A ,